beta
Trial Radar AI
Clinical Trial NCT07018310 (MAHATMAt) for Hematological Malignancy is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Micro Assays for HemATology Malignancies Antibody Treatment (MAHATMAt) 166 Immunotherapy

Not yet recruiting
Clinical Trial NCT07018310 (MAHATMAt) is an interventional study for Hematological Malignancy and is currently not yet recruiting. Enrollment is planned to begin on 1 January 2026 and continue until the study accrues 166 participants. Led by Assistance Publique Hopitaux De Marseille, this study is expected to complete by 1 January 2029. The latest data from ClinicalTrials.gov was last updated on 20 November 2025.
Brief Summary
Hematological malignancy is a disease of the blood. In some cases, this pathology requires therapeutic management, which is not necessarily the case for you. Nevertheless, to improve the management of patients who need it, we are conducting research to assess the state of your immune system. Indeed, the role of the immune system is not limited to controlling infections, but is also important in controlling the prolif...Show More
Official Title

Micro Assays for HemATology Malignancies Antibody Treatment

Conditions
Hematological Malignancy
Other Study IDs
  • MAHATMAt
  • RCAPHM25_0145
  • 2025-A01044-45 (Other Identifier) (APHM)
NCT ID Number
NCT07018310
Start Date (Actual)
2026-01
Last Update Posted
2025-11-20
Completion Date (Estimated)
2029-01
Enrollment (Estimated)
166
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Primary Purpose
Other
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Experimentalblood sampling
blood sampling in patients with hematological malignancies
blood sampling
Additional blood sampling as part of routine care
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Percentages of immune effectors
Percentages of immune effectors responding to stimulation, assessed in patients with hematological malignancies
At the enrollement in the study
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Activation percentages (cytometry) vs. polymorphism expression percentage (molecular biology)
Analysis and comparison of activation percentages (cytometry) vs. polymorphism expression percentage (molecular biology)
At the enrollement
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Male or Female over 18 years of age
  • Patient with a hematological malignancy likely to benefit from immunotherapy (in any form; at the discretion of the referring physician)
  • Before the start of 1st-line treatment, successive lines or before autograft (chemotherapy-free for at least 4 weeks in these cases).
  • Patient has received information about the study and has not expressed opposition.
  • Patient who is a beneficiary or entitled beneficiary of a social security scheme

  • Person in a period of exclusion from another research protocol at the time the non-opposition is signed.

  • Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code, i.e. :

    • Persons deprived of their liberty by judicial or administrative decision
    • Persons subject to psychiatric monitoring under articles L3112-1 and L3113-1 who are not covered by the provisions of article L1121-8
    • Minors
    • Adults under legal protection or unable to express their consent.

  • A person who cannot read and understand the French language well enough to be able to consent to take part in research.

Assistance Publique Hopitaux De Marseille logoAssistance Publique Hopitaux De Marseille
Study Central Contact
Contact: Régis Costello Pr, 0491435817, [email protected]
1 Study Locations in 1 Countries
Assisitance Publique Hôpitaux de Marseille, Marseille, 13005, France
Régis Costello Pr, Contact, 0491435817, [email protected]